Rivfloza™ (nedosiran) injection is a new treatment to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR ≥30 mL/min/1.73 m2.1
Rivfloza™ (nedosiran) injection is a new treatment to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, eg, eGFR ≥30 mL/min/1.73 m2.1
Once-monthly Rivfloza™
Now approved for PH1 patients ages 9 and older
Once-monthly dosing
At-home, self- or caregiver-administered injectionsa
aFor patients 9 to 11 years of age weighing 110 pounds (50 kilograms) or more, Rivfloza™ may be administered by a health care professional or a caregiver using the pre-filled syringe. For patients 9 to 11 years of age weighing less than 110 pounds, Rivfloza™ vials may be administered by a caregiver after proper training, if a health care professional determines that it is appropriate, and with medical follow-up as necessary. Please see full Instructions for Use in full Prescribing Information.
Rivfloza™ will be available to prescribe in early 2024.
For questions about Rivfloza™ or getting patients started on Rivfloza™, please contact our Customer Care Center at 844-906-5099.
Will we see you at the American Society of Nephrology (ASN) Kidney Week 2023?
If you have questions about once-monthly Rivfloza™, come see us in Booth #911 at Kidney Week 2023 in Philadelphia.
Important Safety Information for Rivfloza™
Adverse Reactions
- Most common adverse reaction (reported in ≥20% of patients) is injection site reactions, which include erythema, pain, bruising, and rash.
Indications and Usage
Rivfloza™ (nedosiran) injection 80 mg, 128 mg, or 160 mg is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m2.
Please click here for Rivfloza™ Prescribing Information.
Important Safety Information for Rivfloza™
Adverse Reactions
- Most common adverse reaction (reported in ≥20% of patients) is injection site reactions, which include erythema, pain, bruising, and rash.
Indications and Usage
Rivfloza™ (nedosiran) injection 80 mg, 128 mg, or 160 mg is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m2.
Please click here for Rivfloza™ Prescribing Information.
Reference:
- Rivfloza™ [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2023.